Relapsed or Refractory Classical Hodgkin’s Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 Hodgkin lymphoma (HL) is a B-cell malignancy representing approximately 1 in 10 lymphomas diagnosed in the United States annually. Most patients with HL can be cured with chemotherapy; however, 5-10% will have the refractory disease to frontline therapy, and 10-30% will relapse. For those with relapsed or refractory (r/r) HL, salvage chemotherapy followed by autologous stem cell transplant (ASCT) is standard of care, but half of the patients will subsequently have disease progression. Relapse following ASCT has been associated with exceedingly poor prognosis with a median survival of only 26 months.

·       Hodgkin lymphoma (HL) is a B-cell malignancy, representing approximately 10% of all lymphomas seen in the United States, with an incidence of over 8500 cases per year.

·       Most patients with either limited or advanced stage cHL can be cured with chemotherapy; however, 5–10% will have the refractory disease to frontline therapy, and approximately 10–30% will relapse.

Thelansis’s “Relapsed or Refractory Classical Hodgkin’s Lymphoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Classical Hodgkin’s Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Relapsed or Refractory Classical Hodgkin’s Lymphoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Relapsed or Refractory Classical Hodgkin’s Lymphoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Relapsed or Refractory Classical Hodgkin’s Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032